Prostate biopsy: evolving strategies and perspectives

Affiliations

¹ Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
² Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy. cosimodenunzio@virgilio.it.

Editorial

Antonio Franco et al. Prostate Cancer Prostatic Dis. 2025.

. 2025 Nov 25.

doi: 10.1038/s41391-025-01059-3. Online ahead of print.

¹ Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
² Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy. cosimodenunzio@virgilio.it.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Li EV, Busza AM, Siddiqui MR, Aguiar JA, Keeter M-K, Neill C, et al. Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era. Prostate Cancer Prostatic Dis. 2025;28:795–801. - DOI - PubMed
1. Zambon A, Nguyen T-A, Fourcade A, Segalen T, Saout K, Deruelle C, et al. Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors. Prostate Cancer Prostatic Dis. 2024;27:500–6. - DOI - PubMed
1. Brisbane WG, Priester AM, Ballon J, Kwan L, Delfin MK, Felker ER, et al. Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling. Eur Urol. 2022;82. https://doi.org/10.1016/j.eururo.2022.01.008 .
1. Noujeim JP, Belahsen Y, Lefebvre Y, Lemort M, Deforche M, Sirtaine N, et al. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling. Prostate Cancer Prostatic Dis. 2023;26. https://doi.org/10.1038/s41391-022-00620-8 .
1. Guo S, Zhang J, Wang Y, Jiao J, Li Z, Cui C, et al. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision. Prostate Cancer Prostatic Dis. 2024;27:288–93. - DOI - PubMed